Where are Cochlear (ASX:COH) shares headed in 2022?

The hearing implant device maker has been a darling of long-term investors for decades. But is the stock too expensive now?
The post Where are Cochlear (ASX:COH) shares headed in 2022? appeared first on The Motley Fool Australia. –

Cochlear Limited (ASX: COH) has been a staple for many ASX share portfolios in the past decade.

The hearing device maker has handsomely rewarded its original investors with a 2,350% return, according to Google Finance, and a 13.8% gain over 2021.

However, this year has ended on a sour note, as the share price actually has fallen more than 14% since its August high.

So where to from here? Is it one to buy for 2022?

‘Sales have stagnated’

Redpoint Investment Management chief Max Cappetta told The Motley Fool that “revenue growth has faltered” recently for Cochlear.

“Implant sales have stagnated during the COVID pandemic.”

Despite sound business prospects, Cappetta reckons that the valuation is “stretched” at the moment.

“Our metrics do point to a resurgence in revenue growth but this seems to be fully priced in at present,” he said.

“While there are improving prospects going forward, there also remains the potential for competing products — though we note that the Cochlear’s devices remain clear market leaders.”

Cochlear shares are dividing the experts

It seems Cochlear shares are polarising analysts.

The Motley Fool’s Zach Bristow reported earlier this month that out of 4 major investment houses, one is bearish, one is neutral and two are slightly bullish on the stock.

Goldman Sachs has set a target of $197 a share, which is about a 10% downside from Wednesday morning’s price of $218.18.

“The firm says that Cochlear’s surgery volumes remain at risk due to their elective nature. It notes that Australian surgery numbers are yet to recover to pre-pandemic volumes,” Bristow reported.

“Goldman Sachs recognises these challenges and reckons Cochlear is a sell in a recent note to clients.”

Meanwhile Citi is neutral with a $220 target, while Jarden and Macquarie rate Cochlear as a “buy” with targets of $258 and $256 respectively.

According to CMC Markets, 8 of 12 analysts are recommending a “hold” for Cochlear shares as the year winds down.

The post Where are Cochlear (ASX:COH) shares headed in 2022? appeared first on The Motley Fool Australia.

Should you invest $1,000 in Cochlear right now?

Before you consider Cochlear , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Cochlear wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

2 ASX 50 shares to buy in 2022

What’s the outlook for ASX healthcare shares in 2022?

Why this top broker says the Cochlear (ASX:COH) share price is heading lower

Motley Fool contributor Tony Yoo owns Cochlear Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!